NCT01539889View on ClinicalTrials.gov

Phase-I Study of Radiolabeled DFH-12 (PulmoBind) for Molecular Imaging of the Pulmonary Circulation

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

January 31, 2013

Conditions
Pulmonary DiseasePulmonary Hypertension
Interventions
RADIATION

99mTC-PulmoBind

DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52). Adrenomedullin (AM) is a 52-amino acid peptide produced by many tissues in the body, including the vascular endothelium. 3 radiolabeled doses of PulmoBind will be used in this study (5mCi, 10mCi and 15mCi) 5 healthy subjects per dose for the 5 mci and the 10 mci groups but 10 subjects will be used for the 15 mci group.

Trial Locations (1)

H1T 1C8

Montreal Heart Institute, Montreal

All Listed Sponsors
lead

Montreal Heart Institute

OTHER

NCT01539889 - Phase-I Study of Radiolabeled DFH-12 (PulmoBind) for Molecular Imaging of the Pulmonary Circulation | Biotech Hunter | Biotech Hunter